SG11202005990RA - Process for providing pegylated protein composition - Google Patents
Process for providing pegylated protein compositionInfo
- Publication number
- SG11202005990RA SG11202005990RA SG11202005990RA SG11202005990RA SG11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA
- Authority
- SG
- Singapore
- Prior art keywords
- protein composition
- pegylated protein
- providing
- providing pegylated
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17211124 | 2017-12-29 | ||
| PCT/EP2018/097122 WO2019129876A1 (en) | 2017-12-29 | 2018-12-28 | Process for providing pegylated protein composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005990RA true SG11202005990RA (en) | 2020-07-29 |
Family
ID=60954809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005990RA SG11202005990RA (en) | 2017-12-29 | 2018-12-28 | Process for providing pegylated protein composition |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200323993A1 (en) |
| EP (1) | EP3731871B1 (en) |
| JP (2) | JP7137625B2 (en) |
| KR (1) | KR102523239B1 (en) |
| CN (1) | CN111741770A (en) |
| SG (1) | SG11202005990RA (en) |
| WO (1) | WO2019129876A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3731871B1 (en) * | 2017-12-29 | 2023-10-04 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646438B1 (en) | 1989-03-20 | 2007-11-02 | Pasteur Institut | A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION |
| EP0747485B1 (en) | 1989-11-06 | 1998-12-02 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
| ES2151463T5 (en) | 1989-12-22 | 2012-10-29 | Merck Serono Sa | DNA constructs for activation and modification of endogenous gene expression |
| JP3051145B2 (en) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | Novel polyethylene glycol derivative modified peptide |
| PT101031B (en) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY |
| US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| DE69332377T2 (en) | 1992-07-13 | 2003-07-03 | Bionebraska, Inc. | METHOD FOR MODIFYING RECOMBINANT POLYPEPTIDES |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| HU228488B1 (en) | 1999-01-29 | 2013-03-28 | Amgen Inc | Gcsf conjugates |
| CZ299516B6 (en) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof |
| WO2003000179A2 (en) * | 2001-06-22 | 2003-01-03 | Pharmacia Corporation | Chemically-modified progenipoietin conjugates |
| MXPA05006688A (en) | 2002-12-19 | 2006-02-22 | Nektar Therapeutics Al Corp | Cyanovirin variant-polymer conjugates. |
| EA200700380A1 (en) | 2004-08-31 | 2007-10-26 | Фармация Энд Апджон Компани Ллс | CONJUGATES OF GLYCEROLICOLORBED POLYETHYLENE GLYCOL - HUMAN GROWTH HORMONE, METHOD OF THEIR PRODUCTION AND METHODS OF THEIR APPLICATION |
| WO2007010552A2 (en) * | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
| US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
| AR067537A1 (en) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | PURIFIED POLYPEPTIDES PURIFICATION |
| WO2010033240A2 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| CN102639553A (en) | 2009-11-24 | 2012-08-15 | 诺沃—诺迪斯克保健股份有限公司 | Method of purifying pegylated proteins |
| CA2808748C (en) | 2010-09-14 | 2018-09-11 | Roberto Falkenstein | Method for purifying pegylated erythropoietin |
| EP2838550A1 (en) * | 2012-03-16 | 2015-02-25 | Belrose Pharma Inc. | Polymeric conjugates of c1-inhibitors |
| EP3731873B1 (en) | 2017-12-29 | 2022-01-26 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
| EP3731871B1 (en) | 2017-12-29 | 2023-10-04 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
-
2018
- 2018-12-28 EP EP18830890.2A patent/EP3731871B1/en active Active
- 2018-12-28 SG SG11202005990RA patent/SG11202005990RA/en unknown
- 2018-12-28 WO PCT/EP2018/097122 patent/WO2019129876A1/en unknown
- 2018-12-28 JP JP2020536191A patent/JP7137625B2/en active Active
- 2018-12-28 CN CN201880089651.9A patent/CN111741770A/en active Pending
- 2018-12-28 US US16/957,462 patent/US20200323993A1/en active Pending
- 2018-12-28 KR KR1020207021885A patent/KR102523239B1/en active IP Right Grant
-
2022
- 2022-09-02 JP JP2022139645A patent/JP7541555B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3731871C0 (en) | 2023-10-04 |
| EP3731871A1 (en) | 2020-11-04 |
| WO2019129876A1 (en) | 2019-07-04 |
| JP7137625B2 (en) | 2022-09-14 |
| JP2022169794A (en) | 2022-11-09 |
| US20200323993A1 (en) | 2020-10-15 |
| JP2021508715A (en) | 2021-03-11 |
| EP3731871B1 (en) | 2023-10-04 |
| JP7541555B2 (en) | 2024-08-28 |
| KR20200104380A (en) | 2020-09-03 |
| CN111741770A (en) | 2020-10-02 |
| KR102523239B1 (en) | 2023-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249527A1 (en) | Proteins specific for cd137 | |
| DK3445788T3 (en) | Novel bispecific polypeptides against cd137 | |
| IL288613A (en) | Multispecific proteins | |
| GB201502305D0 (en) | Protein | |
| GB201502306D0 (en) | Protein | |
| GB201503133D0 (en) | Chimeric protein | |
| SG11201704010UA (en) | Fibroin-derived protein composition | |
| ZA201708041B (en) | Novel proteins specific for lag-3 | |
| DK3737402T3 (en) | Modificeret protein | |
| GB201608197D0 (en) | Novel proteins | |
| GB201515745D0 (en) | Proteins | |
| GB201511787D0 (en) | Proteins | |
| IL258570A (en) | Stable protein compositions | |
| EP3463414C0 (en) | Protein interfaces | |
| EP3377633C0 (en) | Recombinant protein production | |
| GB201506223D0 (en) | Chimeric protein | |
| ZA201901862B (en) | Modified factor h binding protein | |
| HK1257745A1 (en) | Peptide composition | |
| GB201513033D0 (en) | Proteins | |
| SG11202006140TA (en) | Process for providing pegylated protein composition | |
| GB2558968B (en) | G Proteins | |
| ZA202003722B (en) | Modified globin proteins | |
| SG11202005952TA (en) | Process for providing pegylated protein composition | |
| SG11202005990RA (en) | Process for providing pegylated protein composition | |
| EP3505624A4 (en) | Composition for anti-rna-virus comprising eprs protein or fragment thereof |